Evotec begins new Oxford Uni digital health partnershipGermany’s Evotec has begun a new strategic partnership with the British AI tech company Sensyne Health and Oxford Share XEvotec begins new Oxford Uni digital health partnershiphttps://pharmaphorum.com/news/evotec-begins-new-oxford-uni-digital-health-partnership/
Bayer begins phase 3 trial testing aflibercept in infant blindnessBayer has begun a late-stage trial of its blockbuster aflibercept eye drug to prevent blindness in premature infants. Share XBayer begins phase 3 trial testing aflibercept in infant blindnesshttps://pharmaphorum.com/news/bayer-begins-phase-3-trial-testing-aflibercept-in-infant-blindness/
Sanofi/Regeneron asthma trial casts doubt on IL-33 class prospectsThe good news for Sanofi and Regeneron is that their interleukin-33-targeting drug seems to work in asthma. The Share XSanofi/Regeneron asthma trial casts doubt on IL-33 class prospectshttps://pharmaphorum.com/news/sanofi-regeneron-asthma-trial-casts-doubt-il-33-class-prospects/
New paediatric use for Allergan’s biosimilar-threatened BotoxAllergan’s Botox has another clinical use after the FDA granted approval for children with upper limb spasticity. The Share XNew paediatric use for Allergan’s biosimilar-threatened Botoxhttps://pharmaphorum.com/news/new-paediatric-use-for-allergans-biosimilar-threatened-botox/
AMAG bags FDA okay for second ‘female Viagra’ drugAMAG Pharma has won US approval for a new drug to treat decreased libido in premenopausal that will Share XAMAG bags FDA okay for second ‘female Viagra’ drughttps://pharmaphorum.com/news/amag-bags-fda-okay-for-second-female-viagra-drug/
Sanofi hands back neurology gene therapy rights to VoyagerSanofi’s Genzyme unit has handed back rights to two neurology gene therapies to US biotech Voyager Therapeutics, as Share XSanofi hands back neurology gene therapy rights to Voyagerhttps://pharmaphorum.com/news/sanofi-hands-back-neurology-gene-therapy-rights-to-voyager/
Boehringer leads investment in digital therapy for myopiaDigital startup Dopavision has raised cash in a seed funding round backed by Boehringer Ingelheim, to develop a Share XBoehringer leads investment in digital therapy for myopiahttps://pharmaphorum.com/news/boehringer-leads-investment-in-digital-therapy-for-myopia/
J&J’s Spravato for depression ‘should be much cheaper’Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer Share XJ&J’s Spravato for depression ‘should be much cheaper’https://pharmaphorum.com/news/jjs-spravato-for-depression-should-be-much-cheaper/
NHS England to prioritise ‘tumour agnostic’ cancer drugsNHS England is to prioritise cancer drugs that target tumours according to their genetic makeup rather than where Share XNHS England to prioritise ‘tumour agnostic’ cancer drugshttps://pharmaphorum.com/news/nhs-england-to-prioritise-tumour-agnostic-cancer-drugs/
